Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359

Courtney V. Fletcher, Marcia A. Testa, Richard C. Brundage, Margaret A. Chesney, Richard Haubrich, Edward P. Acosta, Ana Martinez, Hongyu Jiang, Roy M. Gulick

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

AIDS Clinical Trials Group (ACTG) 359 was a randomized, partially double-blinded factorial study of 6 antiretroviral regimens, all including saquinavir, among HIV-infected persons in whom prior therapy had failed (n = 258). Counts of remaining saquinavir capsules were determined between weeks 0 and 4; at weeks 4, 8, and 16, self-reported adherence was estimated from 2-day report of doses skipped, therapeutic coverage, and percent of doses taken were determined by electronic monitoring devices applied to saquinavir bottles, and the saquinavir 24-hour area under the curve (AUC) was estimated. Relationships were evaluated among these 4 adherence measures and the primary endpoint of week 16 HIV RNA change. Thirty percent of 254 subjects had HIV RNA <500 copies/mL at week 16. Only self-reported adherence and saquinavir AUC were significantly associated with week 16 HIV RNA change (P = 0.019 and 0.023, respectively), and these measures were higher in subjects with week 16 HIV RNA <500 copies/mL (P = 0.03 and 0.008, respectively). The ability to detect a correlation between electronically monitored adherence and virologic response was limited by the small sample size. Self-reported adherence and saquinavir AUC were significant predictors of virologic response, in this evaluation. These findings provide insight into methods of assessing and improving adherence to antiretroviral regimens.

Original languageEnglish (US)
Pages (from-to)301-306
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume40
Issue number3
DOIs
StatePublished - Nov 1 2005

Fingerprint

Saquinavir
Medication Adherence
Acquired Immunodeficiency Syndrome
Clinical Trials
HIV
RNA
Area Under Curve
Aptitude
Sample Size
Capsules
Equipment and Supplies
Therapeutics

Keywords

  • Adherence
  • Antiretroviral therapy
  • Pill counts
  • Self-reported adherence
  • Virologic response

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. / Fletcher, Courtney V.; Testa, Marcia A.; Brundage, Richard C.; Chesney, Margaret A.; Haubrich, Richard; Acosta, Edward P.; Martinez, Ana; Jiang, Hongyu; Gulick, Roy M.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 40, No. 3, 01.11.2005, p. 301-306.

Research output: Contribution to journalArticle

Fletcher, Courtney V. ; Testa, Marcia A. ; Brundage, Richard C. ; Chesney, Margaret A. ; Haubrich, Richard ; Acosta, Edward P. ; Martinez, Ana ; Jiang, Hongyu ; Gulick, Roy M. / Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. In: Journal of Acquired Immune Deficiency Syndromes. 2005 ; Vol. 40, No. 3. pp. 301-306.
@article{cead046a712d4a9d93ce0b821d41022d,
title = "Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359",
abstract = "AIDS Clinical Trials Group (ACTG) 359 was a randomized, partially double-blinded factorial study of 6 antiretroviral regimens, all including saquinavir, among HIV-infected persons in whom prior therapy had failed (n = 258). Counts of remaining saquinavir capsules were determined between weeks 0 and 4; at weeks 4, 8, and 16, self-reported adherence was estimated from 2-day report of doses skipped, therapeutic coverage, and percent of doses taken were determined by electronic monitoring devices applied to saquinavir bottles, and the saquinavir 24-hour area under the curve (AUC) was estimated. Relationships were evaluated among these 4 adherence measures and the primary endpoint of week 16 HIV RNA change. Thirty percent of 254 subjects had HIV RNA <500 copies/mL at week 16. Only self-reported adherence and saquinavir AUC were significantly associated with week 16 HIV RNA change (P = 0.019 and 0.023, respectively), and these measures were higher in subjects with week 16 HIV RNA <500 copies/mL (P = 0.03 and 0.008, respectively). The ability to detect a correlation between electronically monitored adherence and virologic response was limited by the small sample size. Self-reported adherence and saquinavir AUC were significant predictors of virologic response, in this evaluation. These findings provide insight into methods of assessing and improving adherence to antiretroviral regimens.",
keywords = "Adherence, Antiretroviral therapy, Pill counts, Self-reported adherence, Virologic response",
author = "Fletcher, {Courtney V.} and Testa, {Marcia A.} and Brundage, {Richard C.} and Chesney, {Margaret A.} and Richard Haubrich and Acosta, {Edward P.} and Ana Martinez and Hongyu Jiang and Gulick, {Roy M.}",
year = "2005",
month = "11",
day = "1",
doi = "10.1097/01.qai.0000180078.53321.6a",
language = "English (US)",
volume = "40",
pages = "301--306",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359

AU - Fletcher, Courtney V.

AU - Testa, Marcia A.

AU - Brundage, Richard C.

AU - Chesney, Margaret A.

AU - Haubrich, Richard

AU - Acosta, Edward P.

AU - Martinez, Ana

AU - Jiang, Hongyu

AU - Gulick, Roy M.

PY - 2005/11/1

Y1 - 2005/11/1

N2 - AIDS Clinical Trials Group (ACTG) 359 was a randomized, partially double-blinded factorial study of 6 antiretroviral regimens, all including saquinavir, among HIV-infected persons in whom prior therapy had failed (n = 258). Counts of remaining saquinavir capsules were determined between weeks 0 and 4; at weeks 4, 8, and 16, self-reported adherence was estimated from 2-day report of doses skipped, therapeutic coverage, and percent of doses taken were determined by electronic monitoring devices applied to saquinavir bottles, and the saquinavir 24-hour area under the curve (AUC) was estimated. Relationships were evaluated among these 4 adherence measures and the primary endpoint of week 16 HIV RNA change. Thirty percent of 254 subjects had HIV RNA <500 copies/mL at week 16. Only self-reported adherence and saquinavir AUC were significantly associated with week 16 HIV RNA change (P = 0.019 and 0.023, respectively), and these measures were higher in subjects with week 16 HIV RNA <500 copies/mL (P = 0.03 and 0.008, respectively). The ability to detect a correlation between electronically monitored adherence and virologic response was limited by the small sample size. Self-reported adherence and saquinavir AUC were significant predictors of virologic response, in this evaluation. These findings provide insight into methods of assessing and improving adherence to antiretroviral regimens.

AB - AIDS Clinical Trials Group (ACTG) 359 was a randomized, partially double-blinded factorial study of 6 antiretroviral regimens, all including saquinavir, among HIV-infected persons in whom prior therapy had failed (n = 258). Counts of remaining saquinavir capsules were determined between weeks 0 and 4; at weeks 4, 8, and 16, self-reported adherence was estimated from 2-day report of doses skipped, therapeutic coverage, and percent of doses taken were determined by electronic monitoring devices applied to saquinavir bottles, and the saquinavir 24-hour area under the curve (AUC) was estimated. Relationships were evaluated among these 4 adherence measures and the primary endpoint of week 16 HIV RNA change. Thirty percent of 254 subjects had HIV RNA <500 copies/mL at week 16. Only self-reported adherence and saquinavir AUC were significantly associated with week 16 HIV RNA change (P = 0.019 and 0.023, respectively), and these measures were higher in subjects with week 16 HIV RNA <500 copies/mL (P = 0.03 and 0.008, respectively). The ability to detect a correlation between electronically monitored adherence and virologic response was limited by the small sample size. Self-reported adherence and saquinavir AUC were significant predictors of virologic response, in this evaluation. These findings provide insight into methods of assessing and improving adherence to antiretroviral regimens.

KW - Adherence

KW - Antiretroviral therapy

KW - Pill counts

KW - Self-reported adherence

KW - Virologic response

UR - http://www.scopus.com/inward/record.url?scp=27444433808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27444433808&partnerID=8YFLogxK

U2 - 10.1097/01.qai.0000180078.53321.6a

DO - 10.1097/01.qai.0000180078.53321.6a

M3 - Article

C2 - 16249704

AN - SCOPUS:27444433808

VL - 40

SP - 301

EP - 306

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -